Metabolism Disorder TRIZ Cases

Administering uric acid lowering agents addresses elevated uric acid levels that drive insulin resistance, delaying metabolic syndrome onset.

Oral administration of sugar alcohols and polyphenols counteracts antibiotic effects to maintain bacterial abundance and reduce inflammatory disease severity.

PEGylated GLP-1R/GCGR dual agonists extend half-life and reduce toxicity while inhibiting hepatic fibrosis and improving fatty liver conditions.

Whey protein micelles induce delayed maximal aminoacidemia to stimulate muscle protein synthesis.

Exogenous FSP27 peptides restore intermediary regulation of lipid droplet dynamics, reducing circulatory free fatty acids and preventing lipotoxicity.

Composite herbal extracts minimize weight gain and lower triglycerides without synthetic drug side effects.

Fractionated catfish epidermal gel proteins restore Langerhans islets and pancreatic function, addressing the limitation of insulin-only glucose control.

Fluorescent dye dilution tracks T lymphocyte proliferation to isolate antigen-specific regulatory cells, resolving polyspecificity and systemic side effects.

Inhibiting interleukin 11 signaling addresses multiple Hallmarks of Ageing simultaneously to extend healthspan without major side effects.

Ionizable lipid nanoparticles transport CRISPR-Cas9 to liver tissue, reducing ANGPTL3 protein levels and non-HDL lipids while minimizing cumulative toxicity.

Sequential chromatography removes host cell proteins from recombinant human alpha-Gal A to achieve medical-grade purity without serum contaminants.

Incorporating a water-soluble vitamin E derivative into a hydrophilic polymer matrix via spray granulation eliminates organic solvents and reduces caking risks.

A dietary composition uses specific macronutrient ratios to maintain satiety through physiological hormone stimulation.

A cell transplantation kit uses a porous membrane to isolate transplanted cells from host immune responses.

A single injection formulation merges insulin and GLP-1 agonist with adjustable ratios to resolve dosing precision versus treatment complexity.

Targeted PLA2G12A mutations lower blood glucose and insulin levels, resolving inadequate management of fasting glucose in metabolic disorders.

Anise and onion oils inhibit aldose reductase to lower blood glucose, avoiding the drug resistance and side effects of conventional synthetic agents.

Replacing conventional choline sources with choline glycerophosphate prevents hygroscopic degradation and chemical instability in soft gelatin capsules.

Novel Lactobacillus strains regulate blood sugar and cholesterol levels through natural metabolic activity.

Alpha-lipoic acid composition reduces unhealthy body fat proportion exceeding 30% by weight while increasing muscle mass in companion animals.

Alistipes shahii reduces blood lipids and alleviates vascular lesions without toxic side effects from traditional medications.

Inactivated Streptococcus salivarius mediates glucose metabolism via gut microbiota modulation, avoiding metformin side effects.

Acetoacetate prevents acidosis-induced mitochondrial depolarization and autophagy, enabling macrophages to sustain nutrient metabolism and cytokine production.

Polyelectrolyte isotonic saline solution protects liver grafts during transport and transplantation.

A fatty acid side chain covalently attached to a cysteine residue on the FGF21 protein via a thioether bond.

Daily probiotic administration during the third trimester prevents gestational diabetes by modulating gut microbiota to enhance metabolic stability.

Modified starch protects lipophilic health ingredients, reducing extrusion loss during tabletting.

A breath analysis kit detects hyperglycemia likelihood using volatile organic compounds like cymene, butanol, and pentanol.

Administers endothelial progenitor cells alongside antigen-specific therapy to reverse diabetes mellitus by reducing autoimmune infiltration.

Engineered FGF21 variants use specific amino acid substitutions to enhance pharmacological potency and pharmaceutical stability.

Specific antibodies block glucagon signaling to improve glucose tolerance in type 2 diabetes models.

An ALDH3B2 inhibitor agent induces pancreatic duct cells to transdifferentiate into insulin-producing beta-like cells.

Optimizing culture conditions to differentiate pluripotent stem cells into high-purity intestinal midgut endoderm for physiological GLP1 secretion.

Attaching fatty acid chains to CARTp peptides enables blood-brain barrier penetration and neuroprotection via subcutaneous injection.

Anti-LAG-3 antibodies block immune suppression by inhibiting LAG-3 interaction with MHC class II molecules, reactivating T cells.

Bardoxolone methyl activates Nrf2 to reduce weight while minimizing side effects common in conventional anti-obesity drugs.

Modified Angptl4 polypeptides reduce proteinuria and edema while minimizing hypertriglyceridemia side effects.

A triacylglycerol and polyglycerol fatty acid ester composition elevates plasma insulin levels through natural lipid metabolism pathways.

A feed additive composition reduces visceral organ mass and maintenance energy requirements in livestock.

A nutritional composition blends cold-soluble carob with esterified pectins to achieve gastric viscosity above 150 centipoises.

Device validates security data before executing insulin delivery to prevent under-dosing.

PEGylated oxyntomodulin analogues resolve rapid renal clearance by extending half-life and balancing GcgR/GLP-1R activity.

SSEA-3 positive Muse cells isolate non-tumorigenic pluripotency to resolve safety and efficacy trade-offs in diabetic ulcer treatment.

Segmented vitamin pellets with stomach-resistant outer layers ensure targeted release in the large intestine, avoiding premature gastric degradation.

Conjugating glucagon with hydrophilic polymers resolves precipitation at neutral pH while extending half-life for metabolic syndrome treatment.

Liquid enteral nutritional composition with pea protein fraction and controlled fatty acid profile reduces gastric emptying delays in tube feeding patients.

Triglycerides with palmitic acid at the sn-2 position improve body composition in infants.

Enzymatic degradation and ultrafiltration remove furocumarines from bergamot albedo, eliminating toxicity while preserving therapeutic bioflavonoids.

Branched polyethylene glycol linker extends exenatide half-life from 4 to 48 hours, resolving the trade-off between duration and drug activity.